drugset / Trial / NCT03280342

Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramate in Patients With Migraine

NCT03280342

RandomizedCrossoverSingle-blindTreatment

Summary

Crossover, randomized, double blind: Q12h dosing in both periods; matching placebo for evening dosing during XR treatment; target dose: 100mg

Timeline

Start
2017-10-30
Primary completion
2018-08-20
Completion
2018-09-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator Topiramate Small molecule 100 mg

Indications